Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiplatelet therapy

A I Schafer1

  • 1Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

The American Journal of Medicine
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

New antiplatelet agents offer improved prevention of arterial thrombosis compared to aspirin. These therapies target specific platelet activation pathways, showing promise in preventing reocclusion after procedures like coronary angioplasty.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging.

Journal of thrombosis and haemostasis : JTH·2014
Same author

The effect of intermittent operation on a wind-powered membrane system for brackish water desalination.

Water science and technology : a journal of the International Association on Water Pollution Research·2012
Same author

Streptokinase inhibits acute platelet thrombus formation in stenosed dog coronary arteries.

Platelets·2010
Same author

Endothelium-derived Relaxing Factor Inhibits Shear Stress-induced Platelet Aggregation.

Platelets·2010
Same author

Renewable energy powered membrane technology. 2. The effect of energy fluctuations on performance of a photovoltaic hybrid membrane system.

Environmental science & technology·2008
Same author

Renewable energy powered membrane technology. 1. Development and characterization of a photovoltaic hybrid membrane system.

Environmental science & technology·2007
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Practice Changing Updates in Perioperative Medicine Literature 2025. A Systematic Review.

The American journal of medicine·2026
Same journal

Risk of Infection-Related Hospitalization Is More Than Doubled in Cushing's Syndrome vs Matched Controls.

The American journal of medicine·2026
Same journal

Chronic Inflammatory Diseases and Survival among Patients with Pancreatic Cancer in the U.S. Military Health System.

The American journal of medicine·2026
See all related articles

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Background:

  • Arterial thrombosis, a major cause of cardiovascular events, is primarily prevented by antiplatelet therapy.
  • Aspirin, a long-standing antiplatelet drug, has limitations in efficacy for preventing arterial thrombosis.
  • Atherosclerotic vascular injury and disturbed blood flow contribute to platelet-rich thrombus formation.

Purpose of the Study:

  • To review the development and clinical efficacy of novel antiplatelet agents.
  • To compare the mechanisms of action of newer antiplatelet drugs with aspirin.
  • To highlight agents targeting specific platelet activation pathways and aggregation.

Main Methods:

  • Review of clinical trials and scientific literature on antiplatelet therapies.

Related Experiment Videos

  • Analysis of mechanisms targeting platelet adhesion, activation, and aggregation.
  • Categorization of agents based on their molecular targets (e.g., ADP receptors, glycoprotein IIb/IIIa).

    • Main Results:

    • Newer antiplatelet agents target specific steps in platelet activation, offering potentially greater efficacy than aspirin.
    • Agents blocking adenosine diphosphate (ADP) receptors (e.g., clopidogrel) and glycoprotein IIb/IIIa inhibitors show promise.
    • Global interruption of platelet aggregation via glycoprotein IIb/IIIa blockade demonstrated superior efficacy in preventing reocclusion post-coronary procedures.

    Conclusions:

    • Novel antiplatelet therapies provide more targeted approaches to preventing arterial thrombosis.
    • Inhibitors of platelet aggregation, particularly glycoprotein IIb/IIIa blockers, show significant clinical benefit in interventional cardiology.
    • Further research into rationally designed antiplatelet agents is crucial for managing thrombotic disorders.